10 consecutive trading limits! The big monster stock makes a comeback.

What exactly are you speculating about?

Gelonghui FinanceNov 23 17:35

Express News | Xincan New Materials: Currently, there are few manufacturers that can produce DFBP on a large scale.

BreakingsNov 22 08:44

Zhejiang Zhongxin Fluoride Materials (002915.SZ): The company's pharmaceutical intermediates can be used in the field of CRO (Contract Research Outsourcing) pharmaceutical research and development.

Gelonghui October 18th | Zhejiang Zhongxin Fluoride Materials (002915.SZ) stated on the investor interaction platform that the company's pharmaceutical intermediates can be used in the CRO (Contract Research Outsourcing) pharmaceutical research and development field. Pharmaceutical intermediates are important chemical raw materials in the drug synthesis process, playing a key role in the development of new drugs. Currently, the company has formed a representative range of pharmaceutical intermediates including 2,3,4,5-tetrafluorobenzene series, nanosulfacarb acid, and trifluoroacetic acid series, and has a provincial-level small and medium-sized enterprise technology center, a provincial-level enterprise research institute - Zhejiang Zhongxin Fluoride Chemicals and New Materials Research Institute, dedicated to pharmaceutical intermediates.

Gelonghui FinanceOct 18 15:46

Zhongxin Fluoride: Report for the third quarter of 2024

SZSIOct 18 00:00 · Announcements

Zhejiang Zhongxin Fluoride Materials (002915.SZ) released its performance for the first three quarters, with a net loss of 42.99 million yuan.

zhejiang zhongxin fluoride materials (002915.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...

Zhitong FinanceOct 17 16:23

Zhejiang Zhongxin Fluoride Materials (002915.SZ): The net loss in the third quarter was 19.8661 million yuan.

Gelonghui October 17th | Zhejiang Zhongxin Fluoride Materials (002915.SZ) released the third quarter report of 2024, with revenue of 0.382 billion yuan for the reporting period, a year-on-year growth of 14.70%; net income attributable to shareholders of the listed company was -19.8661 million yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -19.9351 million yuan; basic earnings per share was -0.0608 yuan.

Gelonghui FinanceOct 17 16:23